NFSG
ZYNE

Newbridge Financial Services Group’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Newbridge Financial Services Group’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-3,610
Closed -$4.6K – 1362
2023
Q3 		$4.6K Sell
3,610
-1,000
-22% -$873 ﹤0.01% 968
2023
Q2 		$1.5K Sell
4,610
-1,465
-24% -$525 ﹤0.01% 1172
2023
Q1 		$2.61K Hold
6,075
– – ﹤0.01% 1162
2022
Q4 		$3.22K Hold
6,075
– – ﹤0.01% 1144
2022
Q3 		$4K Hold
6,075
– – ﹤0.01% 1105
2022
Q2 		$7K Hold
6,075
– – ﹤0.01% 958
2022
Q1 		$12K Hold
6,075
– – 0.01% 901
2021
Q4 		$17K Buy
6,075
+5,965
+5,423% +$22.1K 0.01% 783
2021
Q3 		$1K Hold
110
– – ﹤0.01% 1357
2021
Q2 		$1K Buy
+110
New +$529 ﹤0.01% 1413

Newbridge Financial Services Group's ZYNE Position: Q4 2023 in Review

Newbridge Financial Services Group sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 3,610 shares — an estimated $4.6K sold.

Newbridge Financial Services Group first reported a position in ZYNE in Q2 2021 and held it in 10 quarters. The position peaked at $17K in Q4 2021. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.

  • Newbridge Financial Services Group reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
  • Newbridge Financial Services Group sold 3,610 Zynerba Pharmaceuticals, Inc shares in Q4 2023, an estimated $4.6K.
  • Newbridge Financial Services Group first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2021 and held it in 10 quarters.
  • Newbridge Financial Services Group's Zynerba Pharmaceuticals, Inc position peaked at $17K in Q4 2021.
  • 0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.

Based on Newbridge Financial Services Group's 13F filing for Q4 2023, filed 28 Mar 2024.